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Abstract
Background: Septoplasty, i.e., surgical correction of the deviated nasal septum, is the most common ear, nose and
throat (ENT) operation in adults. Currently the main indication to perform septoplasty is nasal obstruction. However,
the effectiveness of septoplasty for nasal obstruction in adults with a deviated nasal septum remains uncertain.
Scientific evidence is scarce and inconclusive, and internationally accepted guidelines are lacking. Moreover, there is
no consensus on whether or not septoplasty should be combined with concurrent turbinate surgery. The objective
of the current ongoing trial is to study the effectiveness of septoplasty (with or without concurrent turbinate
surgery) as compared to non-surgical management for nasal obstruction in adults with a deviated nasal septum,
both in terms of subjective (health-related quality of life) as well as objective (nasal patency) outcome measures.
Methods/Design: The study is designed as a pragmatic, multicenter, parallel-group, randomized controlled trial.
A total of 200 adults will be enrolled with nasal obstruction based on a deviated nasal septum and an indication for
septoplasty according to current medical practice in the Netherlands. Participants will be randomized to either
septoplasty (with or without concurrent turbinate surgery as originally indicated by the otorhinolaryngologist) or a
non-surgical watchful waiting strategy. Follow-up visits will be scheduled at 0, 3, 6, 12, and 24 months. During each
follow-up visit, health-related quality of life questionnaires will be administered and measurements of four-phase
rhinomanometry and peak nasal inspiratory flow will be performed. Costs will be studied using a patient-based
diary. Effects of septoplasty on health-related quality of life (primary outcome) and nasal patency will be calculated
as mean differences with 95 % confidence intervals. Subgroup analyses according to gender, age, and severity of
the septal deviation will be performed. All analyses will be performed on an intention-to-treat basis.
Discussion: With the results of this study we aim to contribute to the development of evidence-based guidelines
regarding indications for septoplasty.
Trial registration: Nederlands Trial Register/Dutch Trial Registry (www.trialregister.nl), trial identifying number:
NTR3868. Registered on 21 February 2013.
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Background
Background and rationale
General introduction
Septoplasty is a surgical procedure that aims to straighten
the deviated nasal septum. Septoplasty should not be con-
fused with septorhinoplasty, which is a surgical procedure
that addresses both the nasal septum as well as other
structures of the nose: e.g., alar and triangular cartilages
and nasal bones, most often to improve the appearance of
the nose. Surgical correction of the deviated nasal septum
is the most common ear, nose and throat (ENT) operation
in adults [1]. Annual septoplasty rates, however, differ be-
tween countries. More than 20,000 septoplasties, i.e., 3.8
septoplasties per 10,000 inhabitants, were performed in
England between 2012 and 2013 [2]. In the Netherlands,
10,000 septoplasties, i.e., 6.0 septoplasties per 10,000 in-
habitants, were performed as a single procedure or in
combination with turbinate surgery in 2010 [3].
Mechanisms
Currently, the main indication to perform septoplasty is
nasal obstruction. Nasal obstruction is commonly de-
fined as patient discomfort manifested as a sensation of
insufficient airflow through the nose [4]. The etiology of
nasal obstruction is generally divided into mucosal and
anatomical causes. Nasal septal deviation is the most
common anatomical cause of nasal obstruction [5]. Still,
underlying pathogenesis is often multifactorial. For ex-
ample, nasal septal deviation is commonly accompanied
by compensatory mucosal hypertrophy of the contralat-
eral turbinate [6]. This counterbalanced mechanism is
assumed to protect the more patent nasal side from the
drying and crusting effects of excess airflow [7]. Com-
pensatory hypertrophy can occur in both the inferior as
well as the middle turbinate on the side contralateral to
nasal septal deviation [8]. It has been shown that turbin-
ate enlargement not only comprises mucosal elements,
but may also involve the conchal bone [6]. Since these
changes may not be spontaneously reversible, they
sometimes need to be corrected in conjunction with sep-
tal surgery to prevent nasal obstruction on the non-
deviating side postoperatively [9, 10]. By straightening
the deviated nasal septum and performing concurrent
turbinate surgery, nasal passages are assumed to widen
and as a result nasal breathing is thought to improve.
Existing knowledge
At present the effectiveness of septoplasty in adults with
nasal obstruction and a deviated nasal septum remains
uncertain. Objective measurements do not always correl-
ate with subjective measures to evaluate the effectiveness
of septoplasty [11]. Furthermore, additional benefits of
concurrent turbinate surgery are unknown, and indica-
tions and techniques applied vary considerably [12, 13].
Remarkably, the literature shows a prevalence of nasal
septal deviation of up to 80 %, whereas only a minority
of subjects suffers from nasal obstruction [14]. More im-
portant in this respect, is the fact that scientific publica-
tions on the effects of septoplasty are scarce and
inconclusive, i.e., there is little hard evidence that this
procedure provides any benefit to the patient [14].
As requested by our grant provider, we performed a
computerized literature search in PubMed, Cochrane
Library, Current Controlled Trials, ClinicalTrials.gov,
Database of Abstracts of Reviews of Effects (DARE),
National Health Service Economic Evaluation Database
(NHS EED), and Health Technology Assessment (HTA)
Database, for systematic reviews or randomized trials on
the effectiveness of septoplasty. Studies were included that
met the following criteria: a) randomized trials or system-
atic reviews investigating the effectiveness of septoplasty;
b) the control group received non-surgical management;
and c) clinically relevant outcomes were reported: e.g.,
quality of life or rhinomanometry. Two reviewers (NvH,
MR) independently assessed eligibility of studies. To en-
sure completeness, we did not use any quality assessments
to select within the identified randomized trials. Informa-
tion on patient characteristics (P), interventions (I), the
contrast between interventions (C) and outcome measures
(O) were extracted from all included studies. Initially, 287
studies were identified with our search strategy. All these
studies, however, had to be excluded since they either
studied other interventions (e.g., peri-operative care, post-
operative care, or interventions like nasal packages or
various forms of analgesia), or did not report on a ran-
domized controlled trial. Besides, no data were found re-
garding cost-effectiveness of septoplasty versus watchful
waiting in patients with a deviated nasal septum. Nonethe-
less, we identified a systematic review that showed evi-
dence of a change in nasal airway patency in observational
studies, in which pre-operative and postoperative results
were compared [15]. Furthermore, we actively searched
for observational studies that reported on the effect of
septoplasty on health-related quality of life. We identified
five observational studies that all compared pre-operative
and post-operative health-related quality of life scores
[16–20]. In all studies health-related quality of life in-
creased postoperatively, suggesting the improvement to be
caused by septoplasty. Since all available evidence is based
on observational studies, the risk of bias is high, i.e., the
reported beneficial effects could also be explained by other
factors, such as natural history (no study reported on the
natural course, i.e., the effect of watchful waiting), or ex-
traneous effects (in many patients additional interventions
were performed). Due to these biases the suggested effect
of septoplasty might be overestimated. In short, the lack
of randomized controlled trials precludes a definite con-
clusion concerning the effectiveness of septoplasty.
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Need for a trial
Recently, the benefits of septoplasty have been ques-
tioned, with one of the main concerns being that pos-
sible gains are mainly subjective. In 2010, the
professional association of UK otorhinolaryngologists
published a position paper expressing their concern
that some hospital administrations were suggesting the
abolition or severe restriction of septal surgery, be-
cause of doubts over its benefits [21]. The Dutch ENT
Society also acknowledged the lack of evidence for sep-
toplasty as one the most important knowledge gaps in
current otorhinolaryngology for which a randomized
controlled trial is warranted [22].
Objective
The objective of the current ongoing trial is to study
the effectiveness of septoplasty (with or without con-
current turbinate surgery) as compared to watchful
waiting for nasal obstruction due to a deviated nasal
septum in adults, both in terms of subjective (health-re-
lated quality of life) as well as objective (nasal patency)
outcome measures.
Methods/Design
Trial design
The septumtrial is designed as a pragmatic, multicenter,
parallel-group, two-arm randomized controlled trial.
Study setting
Patient recruitment is currently being conducted at
otorhinolaryngology outpatient clinics in three tertiary
referral hospitals and eighteen secondary referral hospitals
spread over the Netherlands. A multicenter approach was
chosen to increase chances of obtaining the desired power
and to assure representativeness of our sample to the
target population.
Participants
Inclusion criteria
Patients eligible for the trial must comply with all of the
following at randomization:
1. Be age 18 years or above;
2. Provide written informed consent;
3. Have an indication for septoplasty with or without
concurrent turbinate surgery according to current
medical practice, i.e., symptomatic impairment of
the nasal passage due to nasal septal deviation.
In all patients internal exam of the nose should clearly
document that the nasal septal deviation is causing a
mechanical nasal airway obstruction and that the devi-
ation is the primary contributing factor of obstructed
nasal breathing.
Exclusion criteria
Patients selected for septoplasty because of nasal septal
perforation, patients with a history of previous nasal
septal surgery, as well as patients selected for septo-
plasty as part of a cosmetic rhinoplasty procedure,
will be excluded. Patients with untreated allergic rhin-
itis or allergic rhinitis unresponsive to medical treat-
ment will also be excluded. In Dutch clinical practice
most patients are selected for septoplasty because of
symptomatic impairment of the nasal passage due to
nasal septal deviation. However, many patients will
have concurrent complaints, such as impairment of
normal sinus drainage, sleep disorders, or headaches.
These patients can be included if the concurrent
complaints comprise secondary indications. In cases
where these complaints are the main indication for
septoplasty, patients will also be excluded, as will cleft
lip and/or palate patients.
Interventions
Interventions
Included patients will be randomly assigned to either
septoplasty (with or without concurrent turbinate sur-
gery) performed within 6 to 8 weeks after randomization,
or initial non-surgical management. Although septoplasty
is often performed with concurrent surgery for compensa-
tory turbinate hypertrophy, the additional benefits are
questioned [12, 13]. In this trial it is allowed to combine
septoplasty with concurrent turbinate surgery, which will
be accounted for in our subgroup analyses. Septoplasty
and concurrent turbinate surgery both need to be per-
formed according to current medical practice. Several
techniques for performing turbinate surgery are available.
Where applicable, we will register which technique has
been used in each trial patient. Non-surgical manage-
ment includes watchful waiting and medical treatment
such as steroids, antibiotics (intermittent and long-
term), antihistamines, and analgesics. Since the benefits
of septoplasty have never been sufficiently established,
the selection of non-surgical management as comparator
is justified.
Modifications
If they wish to do so, subjects can leave the study at
any time for any reason without any consequences.
Additionally, the investigator can decide to withdraw a
subject from the study for urgent medical reasons. Sub-
jects in the watchful waiting group may need to undergo
surgery because of persisting complaints. As in all surgical
trials, we expect about 30 % of patients to switch from
watchful waiting to surgery. Patients wishing to cross-over
from watchful waiting to surgery will be monitored for the
complete follow-up period.
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Concomitant care
Because of the pragmatic nature of the septumtrial, all pa-
tients in the septoplasty group as well as the watchful
waiting group are allowed to use any kind of escape medi-
cation that is freely available (e.g., over-the-counter medi-
cation such as paracetamol, ibuprofen, normal saline nasal
spray or drops, xylometazoline nasal spray or drops) or
prescribed by their general practitioner or otorhinolaryn-
gologist (such as corticosteroid nasal sprays, antibiotics,
NSAIDs). All medication used as well as all additional
doctor’s visits will be recorded in a patient-based diary to
be able to calculate costs of these additional expenses.
Outcomes
Primary outcome measure
Primary outcome measure will be the difference between
both treatment arms in health-related quality of life, mea-
sured using the Glasgow Benefit Inventory (GBI) and
Glasgow Health Status Inventory (GHSI) questionnaires,
at the primary time point of 1 year after inclusion. While
the GHSI gives a general measure of health status of a per-
son at any specific time, the GBI is maximally sensitive to
a change in health status caused by a specific event (e.g.,
surgical intervention) and can be administered postopera-
tively to measure the effect of the intervention on a pa-
tient’s quality of life [23]. Health-related quality of life was
chosen as primary outcome measure, since septoplasty
aims at improving nasal symptoms rather than merely
straightening the nasal septum. Due to the dual chamber
design of the nose, clinical practice shows no clear correl-
ation between objective (e.g., nasal patency) and subjective
results of septoplasty (e.g., patient sensation of airflow
through the nose) [11]. Moreover, nasal septal deviation
with concurrent reduction of nasal passage can be ob-
served in asymptomatic subjects, while other subjects with
comparable deviations may suffer from severe complaints.
Apparently, what matters is not the nasal passage itself,
but the effect the nasal passage has on someone’s well-
being and daily life. Using quality of life measures in clin-
ical practice ensures that treatment and evaluation focus
on the patient rather than the disease. In addition, by
using quality of life as primary outcome measure, we fa-
cilitate the comparison of treatment effects resulting from
septoplasty with treatment effects of other procedures.
Secondary outcome measures
Secondary outcome measures comprise:
1. Other health-related quality of life measures, i.e., the
EuroQol-5 Dimensions-3 Levels (EQ-5D-3 L), the
Sino-Nasal Outcome Test-22 (SNOT-22), and the
Nasal Obstruction Symptom Evaluation scale (NOSE);
2. Nasal patency as measured with four-phase
rhinomanometry and peak nasal inspiratory flow;
3. Complications and potential side effects;
4. Cost-effectiveness.
The EQ-5D-3 L consists of a descriptive part and a vis-
ual analogue scale (VAS). The descriptive part comprises
the following five dimensions: mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression. The VAS
records the respondent’s self-rated health on a vertical
scale ranging from 0 (worst imaginable health state) to
100 (best imaginable health state) [24]. The SNOT-22 is
developed as a patient-reported outcome measure to use
in chronic rhinosinusitis with or without nasal polyposis
and covers a broad range of health and health-related
quality of life problems, including physical problems, func-
tional limitations, and emotional consequences [25, 26].
The NOSE is developed to assess nasal obstruction and is
validated in adults undergoing septoplasty [16, 27].
The physician researcher, who performs four-phase
rhinomanometry and peak nasal inspiratory flow mea-
surements, has been trained in the use of both devices.
The rhinomanometer was produced by the RhinoLab
GmbH, Freiburg im Breisgau, Germany, and supplied by
Dos Medical BV, ‘s-Hertogenbosch, the Netherlands. The
inspiratory flow meter was produced by Clement Clarke
International, Essex, United Kingdom, and supplied by
PitMedical BV, Enschede, the Netherlands.
Participant timeline
With their informed consent, contact details of potential
candidates will be communicated to the trial center by
otorhinolaryngologists in the participating hospitals.
Subsequently, patients will be contacted by phone by
one of the researchers. The researcher will provide de-
tailed information concerning the trial, answer ques-
tions, and check inclusion and exclusion criteria. When
the patient agrees to participate, a baseline visit will be
scheduled. At this visit, informed consent documents
will be signed and baseline measurements will be per-
formed, consisting of generic and disease-specific
health-related quality of life questionnaires, disease-
specific symptom scores, an ENT examination including
anterior rhinoscopy and nasal endoscopy, four-phase
rhinomanometry, and peak nasal inspiratory flow mea-
surements1. Subsequently, the patient will be random-
ized to either septoplasty, with or without concurrent
turbinate surgery as originally indicated by the otorhino-
laryngologist, or a non-surgical watchful waiting strat-
egy. The patient’s otorhinolaryngologist will be notified
of the result of randomization. If the patient is assigned
to the surgical group, septoplasty is scheduled by the
otorhinolaryngologist within 6 to 8 weeks. A detailed
and standardized operation report will be kept. During
the study, patients and otorhinolaryngologists will be en-
couraged to manage nasal obstruction according to their
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regular practice. If the medical condition of a patient
warrants attention during follow-up, the study physician
will refer the patient to his or her local otorhinolaryn-
gologist for further management. If the otorhinolaryn-
gologist decides to perform septoplasty on a patient in
the watchful waiting group (because of severe com-
plaints persisting under non-surgical management), this
patient will be classified as cross-over and monitored
as planned. All included patients will be invited for
follow-up visits at 3 months, 6 months, 12 months,
and 24 months. During these four follow-up visits,
the same questionnaires and measurements of the
baseline visit are scheduled. Patients will be instructed
to record health-related costs in a patient-based diary,
which will be handed in and checked during each follow-
up visit. Figure 1 shows a flowchart of our trial.
Sample size
Calculations of group size are based on a clinically rele-
vant improvement on the Glasgow scale of 10 (standard
deviation 15). Assuming a quality of life of 70 in the
non-surgical group, and taking an alpha of 0.05 and a
power of 0.90, each treatment arm should include at
least 48 patients. We also performed a power calculation
for the objective rhinomanometry measurements. The
mean value of four-phase rhinomanometry in patients is
about 2.6 Pa/cm3.s-1 (standard deviation 2). Since the
mean value in asymptomatic patients is considered to be
about 1.5 Pa/cm3.s-1, we assume an improvement of
1 Pa/cm3.s-1 to be clinically relevant. Taking an alpha of
0.05 and a power of 0.90, each treatment arm should in-
clude at least 70 patients. To allow for subgroup analyses
according to gender, age, and severity of the septal
deviation, we will include at least 100 adults in each
treatment arm.
Recruitment
Otorhinolaryngologists in 21 Dutch hospitals are in-
volved in patient recruitment. Both the support of the
Dutch ENT Society, as well as the collaboration with a
group of dedicated otorhinolaryngologists set up during
previous studies, will help us to include sufficient patients
in the trial. Screening and recruitment will continue until
the target population (n = 200) is achieved.
Allocation
Sequence generation
Participants will be randomly assigned to either septo-
plasty or non-surgical management. We will use a com-
puterized minimization strategy, i.e., a method of
ensuring balance between prognostic factors in small
samples [28, 29]. Factors that will be taken into ac-
count are severity of the septal deviation, age, gender,
and hospital in which the patient is treated.
Concealment mechanism
Allocation concealment will be ensured, as the result of
randomization will not be released until the patient has
been recruited into the trial, formal informed consent
has been obtained, and all baseline measurements have
been completed.
Implementation
Randomization will be performed by the study physician
during the first study visit, after all baseline measure-
ments have been completed.
Blinding
Trial participants, researchers and otorhinolaryngolo-
gists will not be blinded after assignment to septoplasty
or non-surgical management. As for trial participants
and their otorhinolaryngologists, blinding is not possible
since it would be unethical to propose sham surgery in
the control group. Moreover, blinding of researchers is
not needed since they are only involved in measuring
objective outcomes.
Participate retention
Once a subject is enrolled and randomized, the re-
searchers will make every reasonable effort to follow the
subject for the entire study period. All study visits will
take place at the hospital in which the patient is receiv-
ing treatment. Study visits will be scheduled in agree-
ment with subjects. Moreover, participants will receive a
reminder before every study visit. Questionnaires will be
administered digitally. In this way, we aim to reduce the
burden related to participation in the septumtrial and
minimize loss to follow-up. Individual subjects will not
be replaced after withdrawal.
Data management
Questionnaires will be administered, processed and
stored digitally using the open source survey applica-
tion LimeSurvey (LimeSurvey Project, Hamburg,
Germany). Participant application forms (provided by
otorhinolaryngologists in participating hospitals),
medical history, and data on costs will be processed
and stored using the data management system
MACRO (InferMed, London, United Kingdom). All
data will be handled according to the Dutch law
(Dutch Data Protection Act). Data will be anonymized by
a unique identification number.
Statistical methods
Outcomes
Effects of surgery on health-related quality of life and
nasal passage (rhinomanometry and peak nasal inspira-
tory flow) will be calculated as mean differences with
95 % confidence intervals. For health-related quality of
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Fig. 1 Flow-chart of participant timeline
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life, short-term and long-term effects will be evaluated
at 3, 6, 12, and 24 months follow-up, respectively. All
analyses will be performed on an intention-to-treat basis.
In addition to the intention-to-treat analysis, we will per-
form two sensitivity analyses: 1) a per-protocol analysis
in which we will exclude adults in the watchful waiting
group, who crossed-over to surgery, and 2) an “as
treated” analysis in which we will add adults in the
watchful waiting group, who crossed-over to surgery, to
the septoplasty group. Potential modification of the ef-
fect of septoplasty will be evaluated using Poisson re-
gression including interaction terms for gender, age, and
severity of the septal deviation.
Cost-effectiveness analysis
As evidence regarding the cost-effectiveness of septo-
plasty is lacking, the main objective of the economic
evaluation is to assess the balance between costs and ef-
fects of septoplasty as compared to watchful waiting for
nasal obstruction in patients with a deviated nasal
septum. The economic evaluation is based on the gen-
eral principles of cost-effectiveness analysis (CEA) and
will be performed alongside the randomized controlled
trial. Considering the follow-up duration of 24 months,
primary outcome measures for the economic evaluation
will be costs (direct and indirect) and Quality-adjusted
Life Years (QALY). The incremental cost-effectiveness
ratio (ICER), i.e., cost per QALY gained, will be computed.
Uncertainty will be determined using an appropriate
method, such as bootstrapping, Taylor expansion, or the
Fieller method. A cost-effectiveness acceptability curve
will be derived, with the ability to evaluate efficiency by
using different thresholds (willingness to pay) for 1 QALY.
The impact of uncertainty surrounding deterministic pa-
rameters (e.g., prices) on the ICER will be explored using
one-way sensitivity analyses on the range of extremes.
The cost analysis exists of two main parts. First, volumes
of care will be measured prospectively on patient level
using patient-based diaries and medical records. Patient-
based diaries will record resource uses, such as doctor's
visits, medication, hospital admissions, and surgical inter-
ventions, as well as out-of-pocket expenses such as costs
for over-the-counter drugs. Additionally, traveling time to
the outpatient clinic and related costs will be monitored
using a diary. Where relevant, (missing) diary entries will
be verified by data from medical records. Per arm (septo-
plasty and non-surgical management), full cost prices will
be determined using activity-based costing. Productivity
losses for patients will be estimated using a patient-based
diary and interviews on a 3 to 12 months recall basis by
the physician researcher. The friction cost-method
will be applied following Dutch guidelines [30]. As
second part of the cost analysis, cost prices for each
volume of consumption will be determined. Cost prices
will be multiplied with volumes recorded for each partici-
pant. Again, Dutch guidelines for cost analyses will be
used [30]. Real cost prices will be determined in case no
guidelines or standard prices are available for certain units
of care or resources.
Data monitoring
Participation in the septumtrial carries no risks additional
to those associated with standard care. Therefore, no Data
Monitoring Committee (DMC) is needed. However, the
study is conducted in accordance with principles of Good
Clinical Practice. For this reason we have developed a
monitoring plan for data collection, aiming for:
1. Full monitoring of informed consents;
2. Full monitoring of serious adverse events (SAEs);
3. Monitoring of the first 20 patients at each follow-up
visit, to ensure data quality of the following 180
patients.
Harms
Septoplasty may lead to the following complications:
nasal obstruction, nasal septal hematoma, nasal septal
abscess, saddle nose or other nasal deformity, nasal sep-
tal perforation, epistaxis, acute or chronic rhinitis. All
these complications are rare (occurring in less than 1 %
of all cases) and most of them resolve without additional
treatment. In selected cases, an additional intervention
(drainage of hematoma or abscess, antibiotics, additional
nasal packing, surgical correction of saddle nose or other
nasal deformities) may be needed to resolve the compli-
cation. All adverse events (AEs) will be followed until
they have abated, or until a stable situation has been
reached. Depending on the event, follow-up may require
additional tests or medical procedures as indicated, and/
or referral to the general physician or a medical specialist.
SAEs will be reported until the end of the study.
Ethics and dissemination
Research ethics approval and amendments
The study protocol, informed consent form, and patient
information brochure have been reviewed and approved
by the sponsor (ZonMw, The Netherlands Organization
for Health Research and Development) and the accredited
medical ethics committee (Commission for Research in
Human Subjects, in Dutch: Commissie Mensgebonden
Onderzoek (CMO), region Arnhem – Nijmegen, the
Netherlands). Since the enforcement of the Centrale Com-
missie Mensgebonden Onderzoek (CCMO) External Re-
view Directive in 2012, local medical ethical committees
of local participating centers are no longer involved in
reviewing the study protocol of multicenter research in
the Netherlands. Additional file 1 contains a list of all ap-
proved amendments and Additional file 2 contains the
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completed SPIRIT 2013 checklist, whereas Additional file
3 contains the informed consent form and patient infor-
mation brochure (in Dutch). Additional file 4 provides an
overview of the literature search described in the Back-
ground section.
Consent or assent
Potential participants will be informed by the otorhino-
laryngologist and the physician researcher. Informed
consent documents of all participants are obtained and
co-signed by the physician researcher.
Dissemination policy
Results of the septoplasty trial will be communicated to
participants, healthcare professionals and the public
through newsletters, publications in peer-reviewed jour-
nals and presentations on national meetings of the
Dutch ENT Society.
Discussion
This ongoing pragmatic randomized controlled trial is the
first study to assess the effectiveness of septoplasty com-
pared to non-surgical management for nasal obstruction
due to a deviated nasal septum in adults. So far, all avail-
able evidence for the effectiveness of septoplasty is based
on observational studies. Observational studies, however,
are known to have a high risk of bias. As a result, the
beneficial effects of septoplasty that were reported in pre-
vious studies are possibly overestimated, since the im-
provement after surgery could also be explained by other
factors, such as natural history or extraneous effects.
To assess the effectiveness of interventions and to in-
form decisions about treatment options in clinical
practice, a pragmatic randomized controlled trial re-
mains the design of choice [31].
A major strength of our study is that the effectiveness
of septoplasty is evaluated both in terms of subjective
(health-related quality of life) as well as objective (nasal
patency) outcome measures. Health-related quality of
life is measured with four widely used questionnaires
and nasal patency is assessed by two different methods
(four-phase rhinomanometry and peak nasal inspiratory
flow). Although subjective and objective outcome mea-
sures both provide valuable information about the effects
of septoplasty on nasal obstruction, it is known that sub-
jective and objective outcomes do not necessarily correlate
[11]. We chose health-related quality of life as primary
outcome measure to focus on the patient rather than the
disease, as septoplasty aims at improving nasal symptoms
and not merely straightening the nasal septum.
Another strength of our study is the relatively long
duration of follow-up, i.e., 2 years for each participant.
Follow-up visits will be scheduled at baseline and after 3,
6, 12, and 24 months. Most studies performed so far
have a follow-up varying between 3 months and 1 year.
This provides a distorted view of the effectiveness of sur-
gery, as long-term results tend to differ from short-term
outcomes, especially for turbinate surgery [32]. A follow-
up of 2 years was chosen for this trial in order to evaluate
whether short-term effects of surgery remain present after
a longer period of time. Moreover, it provides insight in the
number of patients wishing to cross-over from watchful
waiting to surgery after the first year of follow-up.
Although necessary for a proper assessment of the ef-
fectiveness of septoplasty, the choice for a non-surgical
control group bears the risk of hampering patient re-
cruitment. Research has demonstrated that a potential
barrier to trial participation is the possibility of being al-
located to a placebo-only or active control intervention
that is perceived to be less desirable than the study
intervention [33]. Since eligible candidates need to have
an indication to have septoplasty performed according
to current medical practice, non-surgical management
may be perceived as a less desirable treatment by both
participants and otorhinolaryngologists. In our experi-
ence, a proper understanding of the rationale and aims
of the study is of great importance to motivate trial
participation.
At the time of submission of this trial protocol, 110 par-
ticipants have been enrolled in the study. Patient recruit-
ment will continue until 2016 to achieve the calculated
sample size of 200 participants. Due to our experiences in
previous ENT trials, we are confident that we will be able
to meet the target sample size and to quantify the effects
of septoplasty in a reliable and precise manner. With the
results of this study we aim to contribute to the develop-
ment of evidence-based guidelines regarding indications
for septoplasty. As the impact of trial results upon policy
and practice depends on their applicability, future research
will focus on the representativeness of our trial sample to
the population at large. However, loss of representative-
ness only affects generalizability of trial results if included
patients differ from eligible but non-included patients with
respect to determinants of the magnitude of treatment ef-
fect, i.e., effect modifiers [34]. In order to evaluate repre-
sentativeness of our trial sample, we will conduct a future
study in which baseline measurements (including demo-
graphic and disease-specific characteristics: e.g., type and
severity of the nasal septal deviation) will be performed in
all patients selected for septoplasty in a Dutch hospital
not participating in the current trial. Moreover, we are
currently collaborating with researchers from University
College London, who have submitted an application for a
comparable randomized controlled trial (RCT) on septo-
plasty for nasal obstruction, in response to a commis-
sioned call from the Health Technology Assessment
Programme of the National Institute for Health Research.
Should this proposal be successful, we will continue
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working together for our shared objective of studying the
effectiveness of septoplasty for nasal obstruction in adults
with a deviated nasal septum.
Trial status
Recruitment began in September 2013 and is currently
ongoing. A total of 110 patients were enrolled by mid-
July 2015.
Endnotes
1For reasons of feasibility, in selected cases health-
related quality of life questionnaires may be adminis-
tered digitally to participants prior to the baseline visit.
In case a subject decides to withdraw informed consent
during the baseline visit, questionnaire derived data will
be destroyed.
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